RT @jpreventionalz1: Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer’s Disease Intervention: What Evidence…
RT @jpreventionalz1: Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer’s Disease Intervention: What Evidence…
RT @jpreventionalz1: Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer’s Disease Intervention: What Evidence…
RT @jpreventionalz1: Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer’s Disease Intervention: What Evidence…
RT @jpreventionalz1: Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer’s Disease Intervention: What Evidence…
Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer’s Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers? https://t.co/8QoIKEIVkQ
RT @jpreventionalz1: Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer’s Disease Intervention: What Evidence…
Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer’s Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?. J Prev Alzheimers Dis. https://t.co/q8InRxaDT2
RT @jpreventionalz1: Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence…
RT @jpreventionalz1: Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence…
RT @jpreventionalz1: Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence…
Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, P... - PubMed - NCBI https://t.co/gnREKcmGni Robust behavioral and psychological outcome data in early symptom
RT @jpreventionalz1: Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence…
Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, P... - PubMed - NCBI https://t.co/gnREKcmGni
The world awaits a drug that can delay or prevent Alzheimer's dementia. What are the challenges to evaluating new candidate drugs? What evidence will be convincing to health plans and meaningful to patients? Original research published in JAPD. https://t.c